Walleye Capital LLC Sells 234,105 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Walleye Capital LLC lessened its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 94.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,183 shares of the biopharmaceutical company’s stock after selling 234,105 shares during the period. Walleye Capital LLC’s holdings in Catalyst Pharmaceuticals were worth $296,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock worth $175,957,000 after buying an additional 390,116 shares in the last quarter. Pacer Advisors Inc. raised its stake in Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after acquiring an additional 151,495 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company’s stock valued at $56,477,000 after acquiring an additional 180,100 shares during the period. Boston Partners boosted its stake in shares of Catalyst Pharmaceuticals by 1.3% in the 4th quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock valued at $27,325,000 after purchasing an additional 16,601 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 6.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock worth $26,023,000 after purchasing an additional 79,182 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling

In related news, insider Brian Elsbernd sold 62,975 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on CPRX shares. Robert W. Baird upped their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. Stephens reissued an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Bank of America reissued a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $32.29.

Catalyst Pharmaceuticals Trading Up 0.3 %

Shares of NASDAQ:CPRX opened at $23.19 on Friday. The stock has a market capitalization of $2.83 billion, a P/E ratio of 19.65, a P/E/G ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.47 and a 1-year high of $26.16. The business has a 50-day moving average price of $22.57 and a two-hundred day moving average price of $22.16.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.